July 27, 2018 — Acumyn was acquired by Elekta, one of the world’s leading radiation therapy companies.
Our team will continue to bring innovative QA solutions to clinics and hospitals worldwide under Elekta banner.
Empowering Confidence in Healthcare.
Our goal is to ensure medical devices are 100% safe for patients. This is a lofty goal and we are working to achieve it following three basic principles:
1) Precision matters – Small mistakes in complex medical devices result in catastrophic results. Our work is governed by a passion for precision.
2) Agility is key – We are lean and responsive, constantly learning from our customers and updating our products to meet their evolving needs.
3) Build by physicists for physicists – We partnered with world-class hospitals and device manufacturers to understand what is needed and so that we build the right product.
Radiation therapy has enabled clinicians to cure more cancer patients than ever before with personalized patient-specific techniques. Evolving technologies in medical imaging devices are enabling better diagnostics and higher precision treatment techniques.
Today, with the acceleration of technological complexity, quality assurance is becoming increasingly critical for hospitals. Current device quality assurance practices are time-consuming and error-prone, and the manual process exhausts much-needed human resources. Fragmented tools and workflows add to complexity and introduce risks to patient safety.
Acumyn, a medical technology company, delivers AQUA, a Quality Assurance software that ensures radiotherapy and medical imaging devices will perform reliably to deliver the best possible care to patients. AQUA was developed at Princess Margaret Cancer Centre, one of the leading cancer research institutions in the world. Building on this expertise, Acumyn has continued development of AQUA to make it the unified QA platform for all medical devices across all departments.
www.acumyn.com.
Company’s Keywords:
quality control management, oncology, radiation therapy, cancer therapy
<2
<2500000
<2014